Dr. Ronald Nahass, MD is an infectious disease specialist in Hillsborough, New Jersey. He is currently licensed to practice medicine in New Jersey. He is affiliated with University Med Center Princeton, Robert Wood Johnson University Hospital, and Saint Peter's University Hospital.
Education & Training
Robert Wood Johnson University Hospital Somerset
Morristown Medical Center
Saint Peter's University Hospital
New Brunswick, NJ
East Mountain Hospital
Belle Mead, NJ
Robert Wood Johnson University Hospital
New Brunswick, NJ
University Medical Center of Princeton at Plainsboro
Medical Guide to Best Doctors Northeast region and National Best Doctor in America
Castle, Connolly, 2014
Acid suppression medications during hospitalization as a risk factor for recurrence of Clostridioides difficile infection: systematic review and meta-analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Mehta, P., Nahass, R. G., Brunetti, L.
Burkitt lymphoma presenting with fever of unknown origin and isolated hypoglossal nerve palsy.
Journal of the American Association of Nurse Practitioners
Seneca, K. H., Nahass, R. G., Adler, R. H.
Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older.
Gerontol Geriatr Med
Flamm, S.,Peng, C. Y.,Shibolet, O.,Nahass, R.,Hwang, P.,Barr, E.,Robertson, M. N.,Haber, B. A.
Thorn-Induced Alternaria septic arthritis and osteomyelitis of the hand
Infect Dis Clin Practice
Li Boning, Boretz R, Nahass RG
Linkage to Care for Hepatitis C Virus (HCV) Among Suburban Heroin Users in New Jersey
Emerg Infect Dis
Akyar E, Seneca KH, Akyar S, Schoefield N, Schwartz MP, Nahass RG
C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)
Dore GJ, Altice F, Litwin AH, Grebely J, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, et al
High efficacy of sofosbuvir/velpatasvir plus gs-9857 for 12 weeks in treatment-experienced genotype 1-6 hcv-infected patients, including those previously treated with direct-acting antivirals
Lawitz E, Kowdley K, Curry M, Reau N, Nguyen M, Kwo P, Jacobson I, Tran T, Nahass RG
Sofosbuvir + PEGInterferon/Ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experineced cirrhotic patients with genotype 2 HCV: The Boson Study
Foster GR, Pianko S, Cooper C, Brown A, Forton D, Nahass RG, et al